

PCL Department Publications - 2003

"A,B,C,D"

Likhodii SS, **Burnham WM**: Calorie restriction may not elevate the threshold of PTZ-induced seizures. *Epilepsy Res.* 57(1):77-8; author reply 79-80. No abstract available (2003).

Murphy P and **Burnham WM**: The effect of kindling on the activity level of Long Evans rats. *Exp. Neurol.* 180: 87-91 (2003).

Likhodii SS, Serbanescu I, Cortez MA, Murphy P, Snead III OC, **Burnham WM**: Anti-convulsant properties of Acetone, a Brain Ketone elevated by the Ketogenic Diet. *Ann. Neurol.* 54: 219-226 (2003).

Lonsdale D, **Burnham WM**: The anticonvulsant effects of progesterone and 5alpha-dihydroprogesterone on amygdala-kindled seizures in rats. *Epilepsia.* 44(12):1494-9 (2003)

Burnham WM: Epilepsy: The Invisible Disability. In: *Disabilities in Ontario.* (2003)

Thompson MD, van's Gravesande KS, Galczenski H, Siminovitch KA, Zamel N, Slutsky A, Drazen JM, George SR, **Burnham WM**, Evans JF, O'Dowd BF: A cysteinyl leukotriene 2 receptor variant is associated with atopy in the population of Tristan da Cunha. *Pharmacogenetics.* 13 (10):641-9 (2003).

Brands B

Brands B, Blake J, Marsh D. Impact of methadone program philosophy changes on early treatment outcomes. *J Addict Dis.* 22(3):19-38 (2003).

Zawertailo LA, **Busto UE**, Kaplan HL, Greenblatt DJ, Sellers EM. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. *J Clin Psychopharmacol.* 23(3):269-80 (2003).

Glass JR, Sproule BA, Herrmann N, Streiner D, **Busto UE**: Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. *J Clin Psychopharmacol.* 23(3):260-8 (2003).

Gafni I, **Busto UE**, **Tyndale RF**, Kaplan HL, Sellers EM. The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. *J Clin Psychopharmacol.* 23(2):169-75 (2003).

Newman D, **Dorian P**, Paquette M, Irvine J, Tang ASL, Woodend K, Connolly S, Lau C. The effect of pacing mode on health-related quality of life improves in the Canadian Trial of Physiologic Pacing (CTOPP). *Am Heart J.* 145: 430-7 (2003).

Gillis A, Philippon F, Cassidy MR, Singh N, **Dorian P**, Love BA, Kerr CR. Guidelines for implantable cardioverter defibrillator follow-up in Canada: A consensus statement of the Canadian Working Group on Cardiac Pacing. *Can J Cardiol.* 19: 21-8 (2003).

Pinter A, **Dorian P**, Paquette M, Ng A, Burns M, Spanu I, Freeman M, Korley V, Newman D. Left ventricular performance during acute rate control in atrial fibrillation: The importance of heart rate and agent used. *J Cardiovasc Pharmacol Ther.* 8: 17-24 (2003).

Crystal E, Kahn S, Roberts R, Thorpe K, Gent M, Cairns JA, **Dorian P**, Connolly S, on behalf of CAMIAT investigators. Chronic amiodarone therapy and the risk of complications after cardiac surgery: Results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). *J Thorac Cardiovasc Surg.* 125: 633-7 (2003).

Lee DS, Green LD, Liu PP, **Dorian P**, Newman DM, Curry Grant F, Tu JV, Alter DA. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: A meta-analysis. *J Am Coll Cardiol.* 41: 1573-82 (2003).

Newman DM, **Dorian P**, Paquette M, Sulke N, Gold MR, Schwartzman DS, Schaaf K, Wood K, Johnson L for the Worldwide Jewel AF AF-Only Investigators. The effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. *Am Heart J.* 145: 841-6 (2003).

Nanthakumar K, **Dorian P**, Paquette M, Greene M, Edwards J, Heng D, Noble J, Newman D. Is inappropriate implantable defibrillator shock therapy predictable? *J Interven Cardiac Electr.* 8: 215-20 (2003).

Baker B, Khaykin Y, Devins G, **Dorian P**, Shapiro C, Newman D. Correlates of therapeutic response in panic disorder presenting with palpitations: heart rate variability, sleep, and placebo effect. *Can J Psychiat.* 48: 381-7 (2003).

Dorian P, Mangat I. Restoring sinus rhythm in atrial fibrillation: A pyrrhic victory? *J Am Coll Cardiol.* 42: 30-2 (2003).

Khaykin Y, Newman D, Kowalewski M, Korley V, **Dorian P**. Biphasic vs. monophasic cardioversion in shock-resistant atrial fibrillation. *J Cardiovasc Electrophysiol.* 14: 868-72 (2003).

Dorian P, Mangat I. Role of amiodarone in the era of the implantable cardioverter defibrillator. *J Cardiovasc Electrophysiol.* 14 (Suppl 9): S78-S81 (2003).

O'Brien BJ, Spath M, Blackhouse G, Severens JL, **Dorian P**, Brazier J. A view from the bridge: agreement between the SF-6D utility algorithm and the health utilities index. *Health Econ.* 12: 975-81 (2003).

Dorian P, Mangat I. Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation (CTAF). *Card Electrophysiol Rev.* 7: 276-9 (2003).

Cervini P, Newman D, **Dorian P**, Edwards J, Greene M, Bhalerao S. Folie a deux: an old diagnosis with a new technology. *Can J Cardiol.* 19: 1539-40 (2003).

Dorian P. Antiarrhythmic drug therapy of atrial fibrillation: Focus on new agents. Electropharmacological Profile and Development of Tedisamil. *J Cardiovasc Pharmacol Ther.* 8 Suppl 1: S27-31 (2003).

Sarkozy A, **Dorian P**. Strategies for reversing shock-resistant ventricular fibrillation. *Curr Opin Crit Care* 9: 189-93 (2003).

Dorian P. Comparison of medical therapy, pacing, and defibrillation in heart failure (Companion) Trial. *Cardiology Scientific Update*, 2003. Sarkozy A, Dorian P. Advances in the acute pharmacologic management of cardiac arrhythmias. *Curr Cardiol Rep.* 5: 387-94 (2003).

"E,F,G"

Tothfalusi T, **Endrenyi L**: Limits for the scaled average bioequivalence of highly variable drugs and drug products. *Pharm. Res.* 20: 382-389 (2003).

Tothfalusi T, **Endrenyi L**, Midha KK: Scaling or wider bioequivalence limits for highly-variable drugs, and for the special case of C max. *Int. J. Clin. Pharmacol. Ther.* 41: 217-225 (2003).

Tothfalusi T, **Endrenyi L**:. Estimation of Cmax and Tmax in populations after single and multiple drug administrations. *J. Pharmacokin. Pharmacodyn.* 30: 363-385 (2003).

El-Ghundi M, O'Dowd BF, **George SR**: Attenuation of sucrose reinforcement in dopamine D1 receptor deficient mice. *Eur J Neurosci* 17: 851-862 (2003).

Karasinska JM, **George SR**, O'Dowd BF: Family 1 G protein-coupled receptor function in the CNS: Insights from gene knockout mice. *Brain Res Reviews* 41: 125-152 (2003).

Vanti WB, Muglia P, Nguyen T, Cheng R, Kennedy JL, **George SR** and O'Dowd BF: Discovery of a null mutation in a human trace amine receptor gene. *Genomics* 82: 531-536 (2003).

Vanti WB, Nguyen T, Cheng R, Lynch KR, **George SR**, O'Dowd BF: Novel human G-protein-coupled receptors. *Biochem Biophys Res Comm* 305: 67-71 (2003).

Lee SP, O'Dowd BF, Rajaram RD, Nguyen T, **George SR**. D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4. *Biochemistry*. 42: 11023-11031 (2003).

George SR, Ng GY, Lee SP, Fan T, Varghese G, Wang C, Deber CM, Seeman P and O'Dowd BF: Blockade of G protein-coupled receptors and the dopamine transporter by a transmembrane domain peptide: novel strategy for functional inhibition of membrane proteins in vivo. *J Pharmacol Exp Ther* 307: 481-489 (2003).

Lee DK, **George SR** and O'Dowd BF: Continued discovery of ligands for G protein-coupled receptors. *Life Sciences* 74: 293-297 (2003).

Lee SP, O'Dowd BF and **George SR**. Homo- and heterooligomerization of G protein-coupled receptors. *Life Sciences* 74: 173-180 (2003).

Madras BK, Fahey MA, Miller GM, De La Garza R, Goulet M, Spealman RD, Meltzer PC, **George SR**, O'Dowd BF, Bonab AA, Livne E, Fischman AJ: Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors. *Eur J Pharmacol* 479: 41-51 (2003).

Rosenberg H, **Grad HA**, Matear DW: The effectiveness of computer-aided, self-instructional programs in dental education: a systematic review of the literature. *J Dent Educ*. 67(5):524-32 (2003).

Sugamori KS, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, **Grant DM**: Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. *Mol Pharmacol*. 64:170-179 (2003).

Eizenman M, Yu LH, **Grupp L**, Eizenman E, Ellenbogen M, Gemar M, Levitan RD: A naturalistic visual scanning approach to assess selective attention in major depressive disorder. *Psychiatry Res*. 118:117-28 (2003).

"H,I,J"

Jacobs S, **Haas DA**, Meechan JG, May S: Injection pain: comparison of the three mandibular block techniques and modulation by nitrous oxide. *J Amer Dental Ass.* 134:869-876 (2003).

Haas DA: Drugs in Dentistry. *Compendium of Pharmaceuticals and Specialties*, L32-35 (2003).

Yao Y, N Pattabiraman N, Michne WF, Huang X-P, and **Hampson DR**: Molecular modeling and mutagenesis of the ligand binding pocket of the mGluR3 subtype of metabotropic glutamate receptor. *J Neurochem* 86: 947-957 (2003).

Kuang D, Yao Y, Wang M, Pattabiramann N, Kotra L, and **Hampson DR**. Molecular similarities in the ligand binding pockets of an odorant receptor and the metabotropic glutamate receptors. *J Biol Chem*, 278: 42551-42559 (2003).

Hodge EM, Diamond ML, McCarry BE, Stern GA, **Harper PA**. Sticky windows: chemical and biological characteristics of the organic film derived from particulate and gas-phase air contaminants found on an urban impervious surface. *Arch Environ Contam Toxicol.* 44(4):421-9 (2003).

Xu BQ, Ishii M, Ding LR, Fischer NE, **Inaba T**: Interaction of serum proteins with CYP isoforms in human liver microsomes: Inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. *Life Sciences* 72: 1953-1962 (2003).

Ramji S, Lee C, **Inaba T**, Patterson AV, Riddick DS: Human NADPH-cytochrome P450 reductase overexpression does not enhance the r.aerobic cytotoxicity of doxorubicin in human breast cancer cell lines. *Cancer Res.* 63:6914-6919 (2003).

Ito S. Is CFTR dysfunction in cystic fibrosis compensated by MRPs? *Pediatr Res.* 54(5):625-6 (2003).

Lee A, Minhas R, Matsuda N, Lam M, **Ito S**. The safety of St. John's wort (*Hypericum perforatum*) during breastfeeding. *J Clin Psychiat.* 64(8):966-8 (2003).

Larsen LA, **Ito S**, **Koren G** . Prediction of milk/plasma concentration ratio of drugs. *Ann Pharmacother.* 37(9):1299-306 (2003).

Woodland C, **Koren G** , Wainer IW, Batist G, **Ito S**. Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. *Can J Physiol Pharmacol.* 81(8):800-5 (2003).

Woodland C, **Koren G** , **Ito S**. From bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example. *J Clin Pharmacol.* 43(7):743-50 (2003).

Hosokawa A, Bar-Oz B, **Ito S**. Use of lipid-lowering agents (statins) during pregnancy. *Can Fam Physician.* 49:747-9 (2003).

Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, Verjee Z, Giesbrecht E, **Koren G** , **Ito S**. Cyclosporine excretion into breast milk. *Transplantation.* 75(12):2144-6 (2003).

Moretti ME, **Koren G** , Verjee Z, **Ito S**. Monitoring lithium in breast milk: an individualized approach for breast-feeding mothers. *Ther Drug Monit.* 25(3):364-6 (2003).

Ito S, Alcorn J. Xenobiotic transporter expression and function in the human mammary gland. *Adv Drug Deliv Rev.* 29;55(5):653-65 (2003).

Ito S, Lee A. Drug excretion into breast milk--overview. *Adv Drug Deliv Rev.* 55(5):617-27 (2003).

"K"

Kalow W: Medical practice, race, and drug use. *Clin. Pharmacol . & Ther.* 73: 132-134 (2003).

Kish SJ. What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease? *Mov Disord.* 18(11):1219-23. (2003).

Andreopoulos S, Li PP, Siu KP, **Kish SJ**, **Warsh JJ**. Altered CTX-catalyzed and endogenous [32P]ADP-ribosylation of stimulatory G protein alphas isoforms in postmortem bipolar affective disorder temporal cortex. *J Neurosci Res.* 72(5): 638-45 (2003).

Furukawa Y, Guttman M, Wong H, Farrell SA, Furtado S, **Kish SJ**. Serum prolactin in symptomatic and asymptomatic dopa-responsive dystonia due to a GCH1 mutation. *Neurology,* 61(2): 269-70 (2003).

Tong J, Ross BM, Schmunk GA, Peretti FJ, Kalasinsky KS, Furukawa Y, Ang LC, Aiken SS, Wickham DJ, **Kish SJ**. Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. *Am J Psychiatry.* 160(5):896-903 (2003).

Guttman M, **Kish SJ**, Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ. 2003 Feb 4;168(3):293-301. Review. Erratum in: CMAJ. 168(5):544 (2003).

Kish SJ. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv Neurol. 91:39-49. (2003)

Knoppert DC, Stempak D, Baruchel S, **Koren G** : Celecoxib in human milk: a case report. Pharmacotherapy. 23: 97-100 (2003).

Hard ML, Iqbal U, Brien JF, **Koren G**: Binding of acetaldehyde to human and Guinea pig placentae in vitro. Placenta 24: 149-54 (2003).

Bar-Oz B, Klein J, Karaskov T, **Koren G** : Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse. Arch Dis Child Fetal Neonatal Ed. 88: F98-F100 (2003).

Uziel Y, Berkovitch M, Gazarian M, **Koren G**, Silverman ED, Schneider R, Laxer RM: Evaluation of eutectic lidocaine/prilocaine cream (EMLA®) for steroid joint injection in Children with juvenile rheumatoid arthritis: A double blind, randomized, placebo controlled trial. J Rheumatol 30: 594-6 (2003).

Koren G , Kearns GL, Reed M, Pons G: Use of healthy children as volunteers in drug studies: the ethical debate. Clin Pharmacol Ther. 73: 147-52 (2003).

Cohen-Kerem R, **Koren G** : Antioxidants and fetal protection against ethanol teratogenicity. Review of the experimental data and implications to humans. Neurotoxicol Teratol. 25: 1-9 (2003).

Moretti ME, Caprara D, Coutinho CJ, Bar-Oz B, Berkovitch M, Addis A, Jovanovski E, Schuler-Faccini L, **Koren G** : Fetal safety of loratadine use in the first trimester of pregnancy: A multicenter study. J Allerg Clin Immunol 111: 479-83 (2003).

Garcia-Bournissen F, Feig DS, **Koren G** : Maternal-fetal transport of hypoglycaemic drugs. Clin Pharmacokinet. 42: 303-13 (2003).

Woodland C, **Koren G** , Ito S: From bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin mifepristone example. J Clin Pharmacol 43: 743-50 (2003).

Woodland C, Wainer I, **Koren G** , Ito S: Verapamil metabolites - potential P-glycoprotein mediated multidrug resistance reversal agents. Can J Physiol Pharmacol 81: 800-5 (2003).

Mungan N, Wilson TW, Nischalk K, Khattak S, Ho T, **Koren G** , Levin A: Life-threatening complications of Alphagan in infants. JAAPOS: 7: 69-70 (2003).

Koren G : Advancing FASD prevention and care through research. JFAS Int 1: e1 (2003).

Koren G : We work in boxes that do not talk to each other. Op cit. 1: e12 (2003).

Rouleau M, Levichek Z, **Koren G** : Are mothers who drink heavily in pregnancy victims of FAS. Op cit. 1: e4 (2003).

Chandra K, Ho E, Sarkar M, Wolpin J, **Koren G** : Characteristics of women using marijuana in pregnancy and their reported effects on symptoms of NVP. Op cit. 1: e13 (2003).

Boskovic R, Einarson A, Maltepe C, Wolpin J, **Koren G** : Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing. J Obstet Gynaecol Can. 25: 830-3 (2003).

Parshuram CS, Ng GY, Ho TK, Klein J, Moore AM, Bohn D, **Koren G** : Discrepancies between ordered and delivered concentrations of opiate infusion in critical care. Crit Care Med. 31: 2483-7 (2003).

French AE, Grant R, Weitzman S, Ray JG, Vermeulen MJ, Sung L, Greenberg M, **Koren G** : Folic acid food fortification is associated with a decline in neuroblastoma. Clin Pharmacol Ther. 74: 288-94 (2003).

Koren G : Healthy children as subjects in pharmaceutical research. Theor Med Bioeth. 24: 149-59 (2003).

Sung L, Greenberg ML, **Koren G** , Tomlinson GA, Tong A, Malkin D, Feldman BM: Vitamin E: the evidence for multiple roles in cancer. Nutr Cancer. 46: 1-14 (2003).

Larsen LA, Ito S, **Koren G** : Prediction of milk/plasma concentration ratio of drugs. Ann Pharmacother. 37: 1299-306 (2003).

Koren G , Matsui D, Bailey B: DEET-based insect repellents: safety implications for children and pregnant lactating women. CMAJ. 169: 209-12 (2003).

Till C, Rovet JF, **Koren G** , Westall CA: Assessment of visual functions following prenatal exposure to organic solvents. Neurotoxicology. 24: 725-31 (2003).

Kozer E, Verjee Z, Emelianova S, **Koren G** : A patient with seizures and a positive drug screen: three wrongs don't make a right. Can J Clin Pharmacol. 10: 63-6 (2003).

Chandra K, Magee L, Einarson A, **Koren G** : Nausea and vomiting in pregnancy: results of a survey that identified interventions used by women to alleviate their symptoms. J Psychosom Obstet Gynaecol. 24: 71-5 (2003).

Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, **Koren G** : Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. *Birth Defects Res Part B Dev Reprod Toxicol.* 68:70-84 (2003).

Ratnapalan S, Potylitsina Y, Tan LH, Roifman M, **Koren G** : Measuring a toddler's mouthful: toxicologic considerations. *J Pediatr.* 142: 729-30 (2003).

Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, Verjee Z, Giesbrecht E, **Koren G** , Ito S: Cyclosporine excretion into breast milk. *Transplantation.* 75: 2144-6 (2003).

Juurlink DN, Tenenbein M, **Koren G** , Redelmeier DA: Iron poisoning in young children: association with the birth of a sibling. *CMAJ.* 168: 1539-42 (2003).

French AE, Soldin SJ, Soldin OP, **Koren G** : Milk transfer and neonatal safety of tacrolimus. *Ann Pharmacother.* 37: 815-8 (2003).

Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, **Koren G** : Transfer of Insulin Lispro Across the Human Placenta: In vitro perfusion studies. *Diabetes Care.* 26: 1390-4 (2003).

Kozer E, Scolnik D, Agamata WM, Weiss SK, Verjee ZH, **Koren G** : Utility of antiepileptic drug monitoring in the pediatric emergency department. *Ther Drug Monit.* 25: 17-21 (2003).

Koren G , Navioz Y: Historical perspective: the original description of fetal alcohol spectrum disorder in France, 1967. *Op cit.* 25: 131 (2003).

Moretti ME, **Koren G** , Verjee Z, Ito S: Monitoring lithium in breast milk: an individualized approach for breast-feeding mothers. *Op cit.* 25: 364-6 (2003).

Chan D, Bar-Oz B, Pellerin B, Paciorek C, Klein J, Kapur B, Farine D, **Koren G** : Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto. *Op cit.* 25: 271-8 (2003).

Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, **Koren G** : A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. *Can J Psychiatry.* 48: 106-10 (2003).

Chan B, **Koren G** : Pharmacological treatment for pregnancy women who smoke cigarettes. *Tobacco Induced Diseases.* 1: 165-75 (2003).

Shuhaiber S, **Koren G** , Boskovic R, Einarson TR, Soldin OP, Einarson A: Seroprevalence of *Toxoplasma gondii* infection among veterinary staff in Ontario, Canada (2002): Implications for teratogenic risk. *BMC Infect Dis.* 3: 8 (2003).

Ratnapalan S, Griffiths K, Costei AM, Benson L, **Koren G** : Digoxin-carvedilol interactions in children. *J Pediatr.* 142: 572-4 (2003).

Koren G, King S, Knowles S, Phillips E: Ribavirin in the treatment of SARS: A new trick for an old drug? CMAJ. 168: 1289-92 (2003).

Lyszkiwicz DA, Levichek Z, Kozar E, Yagev Y, Moretti M, Hard M, **Koren G** : Bioavailability of a pediatric amlodipine suspension. *Pediatr Nephrol*. 18: 675-8 (2003).

Goldman RD, **Koren G** : Taking St. John's wort during pregnancy. *Can Fam Physician*. 49: 29-30 (2003).

French AE, **Koren G** : Motherisk Team. Effect of methotrexate on male fertility. *Op cit*. 49: 577-8 (2003).

Sivojelezova A, Einarson A, Shuhaiber S, **Koren G** : Motherisk Team. Trimethoprim-sulfonamide combination therapy in early pregnancy. *Op cit*. 49: 1085-6 (2003).

Michael O, Goldman RD, **Koren G** : Motherisk Team. Safety of colchicine therapy during pregnancy. *Op cit*. 49: 967-9 (2003).

Koren G : Exposure to electromagnetic fields during pregnancy. *Op cit*. 49: 151-153 (2003).

Ratnapalan S, Bona N, **Koren G** : Motherisk Team. Ionizing radiation during pregnancy. *Op cit*. 49: 873-4 (2003).

Goldman RD, **Koren G** : Anorexia nervosa during pregnancy. *Op cit*. 49: 425-6 (2003).

Goldman RD, Einarson A, **Koren G** : Electric shock during pregnancy. *Op cit*. 49: 297-8 (2003).

"L"

Lanctôt KL, Herrmann N, LouLou M. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. *J Psychiatry Neurosci*. 28(1):13-26 (2003).

Lanctôt KL, Mittmann N, Bradley-Kennedy C, Oh PI. Drug evaluation of meloxicam in an Ontario drug benefit-eligible population. *Drug Benefit Trends*, 15 suppl C (June): 20-29 (2003).

Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR. Efficacy and safety of second generation cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. *CMAJ*. 169(6):557-564 (2003).

Wu G, **Lanctôt KL**, Herrmann N, Moosa S, Oh PI. The cost-benefit of cholinesterase inhibitors in mild to moderate dementia--A willingness-to-pay approach. *CNS Drugs*, 17(14):145-57 (2003).

Lê AD, Wang A, Harding S, Juzysch W, and Shaham Y: Nicotine increases alcohol self-administration and reinstates alcohol seeking in rats. *Psychopharmacol.* 168: 216-221 (2003).

Erb S, Funk D and **Lê AD**: Prior repeated exposure to cocaine potentiates locomotor responsivity to central injections of corticotropin-releasing factor (CRF) in rats. *Psychopharmacol.* 170: 383-389 (2003).

Funk D, Li Z, Shaham Y, **Lê AD**: Effect of blockade of corticotrophin Releasing Factor receptors in the Median Raphe nucleus on stress-induced c-Fos mRNA in the rat brain. *Neurosci.* 122:1-4 (2003).

Chang A, **Li PP**, Warsh JJ. cAMP-Dependent protein kinase (PKA) subunit mRNA levels in postmortem brain from patients with bipolar affective disorder (BD). *Brain Res Mol Brain Res.* 116(1-2):27-37 (2003).

Andreopoulos S, **Li PP**, Siu KP, Kish SJ, Warsh JJ. Altered CTX-catalyzed and endogenous [32P]ADP-ribosylation of stimulatory G protein alphas isoforms in postmortem bipolar affective disorder temporal cortex. *J Neurosci Res.* 72(5):638-45 (2003).

Chang A, **Li PP**, Warsh JJ. Altered cAMP-dependent protein kinase subunit immunolabeling in post-mortem brain from patients with bipolar affective disorder. *J Neurochem.* 84(4):781-91. Erratum in: *J Neurochem.* 85(1):286. (2003).

"M"

Arundine M, Chopra GK, Wrong A, Lei S, Aarts MM, **MacDonald JF** , Tymianski M. Enhanced vulnerability to NMDA toxicity in sublethal traumatic neuronal injury in vitro. *J Neurotrauma.* 20(12):1377-95. (2003).

Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, **MacDonald JF** , Tymianski M. A key role for TRPM7 channels in anoxic neuronal death. *Cell*, 115(7):863-77 (2003).

Jackson MF, Joo DT, Al-Mahrouki AA, Orser BA, **MacDonald JF** . Desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors facilitates use-dependent inhibition by pentobarbital. *Mol Pharmacol.* 64(2):395-406 (2003).

Kotecha SA, **MacDonald JF** . Signaling molecules and receptor transduction cascades that regulate NMDA receptor-mediated synaptic transmission. *Int Rev Neurobiol.* 54:51-106. (2003).

Kotecha SA, Jackson MF, Al-Mahrouki A, Roder JC, Orser BA, **MacDonald JF** . Co-stimulation of mGluR5 and N-methyl-D-aspartate receptors is required for potentiation of

excitatory synaptic transmission in hippocampal neurons. *J Biol Chem.* 278(30):27742-9 (2003)
Epub May 09, 2003.

Milgram NW . Cognitive experience and its effect on age-dependent cognitive decline in beagle dogs. *Neurochem Res.* 28(11):1677-82. (2003).

Nippak PM, Chan AD, Campbell Z, Muggenburg B, Head E, Ikeda-Douglas CJ, Murphey H, Cotman CW, **Milgram NW** . Response latency in *Canis familiaris*: mental ability or mental strategy? *Behav Neurosci.* 117(5):1066-75 (2003).

Siwak CT, Tapp PD, **Milgram NW** . Adrafinil disrupts performance on a delayed nonmatching-to-position task in aged beagle dogs. *Pharmacol Biochem Behav.* 76(1):161-8 (2003).

Siwak CT, Tapp PD, Zicker SC, Murphey HL, Muggenburg BA, Head E, Cotman CW, **Milgram NW** . Locomotor activity rhythms in dogs vary with age and cognitive status. *Behav Neurosci.* 117(4):813-24 (2003).

Tapp PD, Siwak CT, Estrada J, Holowachuk D, **Milgram NW** . Effects of age on measures of complex working memory span in the beagle dog (*Canis familiaris*) using two versions of a spatial list learning paradigm. *Learn Mem.* 10(2):148-60 (2003).

Tapp PD, Siwak CT, Estrada J, Head E, Muggenburg BA, Cotman CW, **Milgram NW** . Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. *Learn Mem.* 10(1):64-73 (2003).

Go L., **Mitchell J**. Palmitoylation is required for membrane association of activated but not inactive invertebrate visual Gq alpha. *Comp Biochem. Physiol. Part B.* 135: 601-609 (2003).

Mayeenuddin LH., **Mitchell J**. Squid visual arrestin: cDNA cloning and calcium-dependent phosphorylation by rhodopsin kinase (SQRK). *J. Neurochem.*85: 592-600 (2003).

Cornish P, **Mittmann N**, Gomez M, Cartotto RC, Fish JS. Cost of medications in patients admitted to a burn center. *Am J Clin Dermatol* 4(12):861-7 (2003).

Lancot KL, **Mittmann N**, Bradley-Kennedy C, Oh PI. Drug evaluation of meloxicam in an Ontario drug benefit eligible population. *Arthritis Trends*, 15 (Suppl C): 20-29 (2003).

Nottage M, McLachlan S, Brittain M, Oza A, Hedley D, Feld R, Siu LL, Pond G, **Moore MJ**. A randomized double blind study of oral sucralfate to prevent and treat flouropirimidine induced stomatitis. *Supportive Care in Cancer*, 11:41-47 (2003).

Chung PW, Warde PR, Panzarella T, Bayley AJ, Catton CN, Milosevic MF, Jewett MA, Sturgeon JF, **Moore MJ**, Gospodarowicz MK. Appropriate radiation volume for stage IIA/B testicular seminoma. *Int J Radiat Oncol Biol Phys*. 56:746-8 (2003).

Davis AJ, Gelmon KA, Siu LL, **Moore MJ**, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK, Eisenhauer EA. Phase I and pharmacologic study of the human DNA methyltransferase (MeTase) antisense oligonucleotide MG98 given as a 21-day continuous infusion every 4 weeks. *Investigational New Drugs* 21:85-97 (2003).

Townsley C, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason G, Stewart D, Goel R, Ruether JD, Siu LL, Jolivet J, McIntosh L, Seymour L, **Moore MJ**. A phase II study of troxacitabine (BCH-4556) in patients with advanced and/or recurrent renal cell carcinoma. A trial of the National Cancer Institute of Canada-Clinical Trials Group. *J Clin Oncol*, 21:1524-9 (2003).

Townsley C, **Moore MJ**. The evolving role of irinotecan in the treatment of colorectal cancer in Canada [review]. *Current Oncology*, 9:37-41 (2003).

Moore MJ. Men should be treated for hormone refractory prostate cancer with systemic chemotherapy when they are symptomatic *Can J*. 2003 10: 2038-9 (2003).

Ribic C, Sargent D, **Moore MJ**, Thibodeau S, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite instability as a predictor of survival benefit from 5-FU based adjuvant chemotherapy in colon cancer. *New Engl J Med*. 349:247-57 (2003).

Moore MJ, Hamm J, Dancy J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Tu D, Zee B, Humphrey R, Seymour L. A Comparison of Gemcitabine versus the Matrix Metalloproteinase Inhibitor BAY 12-9566, in Patients with Advanced or Metastatic Adenocarcinoma of the Pancreas. A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*. 21:3296-302, 2003.

Ernst DS, Tannock IF, Winkvist EW, Venner PM, Reyno L, **Moore M**, Chi K, Ding K, Elliott C, Parulekar W. Randomized, Placebo Controlled Trial of Mitoxantrone/Prednisone (MP) and Clodronate (CL) Versus Mitoxantrone/Prednisone Alone in Patients with Hormone Refractory Prostate Cancer (HRPC) and Pain. *J Clin Oncol*. 21:3335-42 (2003)

Chen X, Oza AM, Kusenda Z, Yi Q-L, Hochman D, **Moore MJ**, Davis AJ, Siu LL. Phase I Study of Cisplatin, Irinotecan, and Epirubicin Administered Every 3 Weeks in Patients with Advanced Solid Tumors. *Br J Cancer*, 89 :617-24 (2003).

Winqvist E, Ernst DS, Jonker D, **Moore MJ**, Segal R, Lockwood G, Rodgers A. Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced, unresectable or metastatic transitional cell carcinoma of the urothelial tract. *Eur J Cancer*. 39:1866-71 (2003).

"N"

Felix S, Sproule BA, Hardy BG, **Naranjo CA**. Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. *J Clin Psychopharmacol*. 23(5):471-8 (2003).

Hall J, **Naranjo CA**, Sproule BA, Herrmann N. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. *J Clin Psychopharmacol*. 23(4):349-57 (2003).

Shapiro LE, Knowles SR, Weber E, **Neuman MG**, Shear NH: Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. *Drug Safety* 26(3): 187-95 (2003).

Ben-Ari Z, Schmilovitz-Weiss H, Belinki A, Pappo O, Sulkes J, **Neuman MG**, Kaganovsky E, Kfir B, Tur-Kaspa R, Klein T. Circulating soluble cytochrome c in liver disease as a marker of apoptosis. *J Intern Med*. 254(2):168-75 (2003).

Jacobson-Brown P, **Neuman MG**: Colon Polyps and Cytokines: Emerging Immunological Mechanisms (ditorial). *Rom J Gastroenterology*, vol 12, 3:207-214 (2003)

Turrone P, Remington G, Kapur S and **Nobrega JN**. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement (VCM) syndrome in rats. *Psychopharmacol*. 165:166-171 (2003).

Kapur S, VanderSpeck SC, Brownlee BA and **Nobrega JN**. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition – a suggested solution based on in vivo occupancy. *J Pharmacol and Experl Ther* 305:625-631 (2003).

Wilson AA, Johnson DP, Mosley D, Hussey D, Ginovart N, **Nobrega JN**, Garcia A and Houle S. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. *Nuclear Med and Bio*. 30:85-92 (2003).

Turrone P, Remington G, Kapur S, and **Nobrega JN**. Differential effects of continuous versus transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. *Neuropsychopharmacol*. 28:1433-1439 (2003).

Moreira KM, Hipólido DC, **Nobrega JN**, Bueno OFA, Tufik S and Oliveira MGM. Deficits in avoidance responding after paradoxical sleep deprivation are not associated with altered [3H]pirenzepine binding to M1 muscarinic receptors in rat brain. *Brain Res.* 477:31-37 (2003).

Quadros IMH, Souza-Formigoni MLO, Fornari RV, **Nobrega JN**, Oliveira MGM: Is behavioral sensitization to ethanol associated to contextual conditioning in mice? *Beh Pharmacol.* 14:129-136 (2003).

Ono M, Wilson A, **Nobrega J**, Westaway D, Verhoeff P, Zhuang ZP, Kung MP, Kung HF. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. *Nuclear Med and Bio.* 30:565-571 (2003).

"O"

Galati G and **O'Brien PJ**. Cytoprotective and anticancer properties of coenzyme Q versus capsaicin. *Biofactors* 18,129-136 (2003)

Chan TS and **O'Brien PJ**. Hepatocyte metabolism of coenzyme Q1 (ubiquinone-5) to its sulfate conjugate decrease its antioxidant activity. *Biofactors* 18, 207-218 (2003)

Bruce WR, Furrer R, Shangari N, **O'Brien PJ**, Medline A, Wang Y. Marginal dietary thiamin deficiency induces the formation of colonic aberrant crypt foci (ACF) in rats. *Cancer Lett.* 202, 125-9 (2003)

Shangari N, Bruce WR, Poon R, **O'Brien PJ**. Toxicity of glyoxals--role of oxidative stress, metabolic detoxification and thiamine deficiency. *Biochem Soc Trans.* 31, 1390-3 (2003)

Beard KM, Shangari N, Wu B, **O'Brien PJ**. Metabolism, not autoxidation, plays a role in alpha-oxoaldehyde- and reducing sugar-induced erythrocyte GSH depletion: relevance for diabetes mellitus. *Mol Cell Biochem.* 252, 331-8 (2003)

Abdollahi M, Subrahmanyam V, Chan TS and **O'Brien PJ**. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. *Mol Cell Biochem.* 252, 205-211 (2003)

Chan TS, Galati G, Pannala AS, Rice-Evans C and Galati G and **O'Brien PJ**. Cytoprotective and anticancer properties of coenzyme Q versus capsaicin. *Biofactors* 18,129-136 (2003)

Moridani MY, Siraki A and **O'Brien PJ**. Quantitative structure toxicity relationships for phenols toxicity in isolated rat hepatocytes. *Chemico-Biol. Interactions.* 145, 213-223 (2003).

Moridani MY and **O'Brien PJ**. Dietary flavonoid iron complexes as cytoprotective superoxide radical scavengers. *Free Radic. Biol. Med.* 34, 243-253 (2003).

Moridani MY, Cheon SS, Khan S, **O'Brien PJ**. Metabolic activation of 3-hydroxyanisole by isolated rat hepatocytes. *Chem Biol Interact.* 142, 317-33 (2003)

Niknahad H, Siraki AG, Shuhendler A, Khan S, Teng S, Galati G, Easson P, Poon R and **O'Brien PJ**. Modulating carbonyl cytotoxicity in intact rat hepatocytes by inhibiting carbonyl metabolizing enzymes. I - Aliphatic alkenals. *Chemico-Biol. Interacns.* 143-144, 107-117 (2003).

Niknahad H, Shuhendler A, Galati G, Siraki AG, Easson P, Poon R and **O'Brien PJ**. Modulating carbonyl cytotoxicity in intact rat hepatocytes by inhibiting carbonyl metabolizing enzymes. II – Aromatic alkenals. *Chemico-Biol. Interacns.* 143-144, 119-128 (2003)

El-Ghundi M, **O'Dowd BF**, George SR: Attenuation of sucrose reinforcement in dopamine D1 receptor deficient mice. *Eur J Neurosci* 17: 851-862 (2003).

Karasinska JM, George SR, **O'Dowd BF**: Family 1 G protein-coupled receptor function in the CNS: Insights from gene knockout mice. *Brain Research Reviews* 41: 125-152 (2003).

Vanti WB, Muglia P, Nguyen T, Cheng R, Kennedy JL, George SR and **O'Dowd BF**: Discovery of a null mutation in a human trace amine receptor gene. *Genomics* 82: 531-536 (2003).

Vanti WB, Nguyen T, Cheng R, Lynch KR, George SR, **O'Dowd BF**: Novel human G-protein-coupled receptors. *Biochem and Biophys Res Communications* 305: 67-71 (2003).

Lee SP, **O'Dowd BF**, Rajaram RD, Nguyen T, George SR. D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4. *Biochemistry.* 42: 11023-11031 (2003).

George SR, Ng GY, Lee SP, Fan T, Varghese G, Wang C, Deber CM, Seeman P and **O'Dowd BF**: Blockade of G protein-coupled receptors and the dopamine transporter by a transmembrane domain peptide: novel strategy for functional inhibition of membrane proteins in vivo. *J Pharmacol and Exper Ther* 307: 481-489 (2003).

Lee DK, George SR. and **O'Dowd BF**: Continued discovery of ligands for G protein-coupled receptors. *Life Sciences* 74: 293-297 (2003).

Lee SP, **O'Dowd BF** and George SR: Homo- and hetero-oligomerization of G protein-coupled receptors. *Life Sciences* 74: 173-180 (2003).

Tanaka H, Yoshida T, Miyamoto N, Motoike T, Kurosu H, Shibata K, Yamanaka A, Williams SC, Richardson JA, Tsujino N, Garry MG, Lerner MR, King DS, **O'Dowd BF**, Sakurai T, Yanagisawa M: Characterization of a family of endogenous neuropeptide ligands for the G protein-coupled receptors GPR7 and GPR8. *Proceedings of the National Academy of Sciences U S A.* 100: 6251-6256, (2003).

Madras BK, Fahey MA, Miller GM, De La Garza R, Goulet M, Spealman RD, Meltzer PC, George SR, **O'Dowd BF**, Bonab AA, Livne E, Fischman AJ: Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors. *Eur J Pharmacol* 379: 41-51 (2003).

"P,Q"

Amer RK, **Pace-Asciak CR** and Mills LR: A lipoxygenase product, hepoxilin A3, enhances NGF-dependent neurite regeneration post-axotomy in rat superior cervical ganglion neurons in vitro. *Neuroscience*, 116: 935 – 946 (2003).

Pace-Asciak CR: Development of Novel Anti-inflammatory and Anti-diabetic Drugs. Proceedings of the International Conference of Essential Fatty Acids and Eicosanoids, AOCS Press, Champaign, Ill. USA, Invited Paper, pp. 247-250 (2003).

Qiao N, Lam J, Reynaud D, Abdelhaleem M and **Pace-Asciak CR**: The hepoxilin analog, PBT-3, induces apoptosis in BCR-ABL-positive K562 cells, *J. Anti-Cancer Res.*, 23: 3617-3622 (2003).

Belik J, Jankov RP, Pan J, Yi M, **Pace-Asciak CR** and Tanswell AK: Effect of 8-Isoprostaglandin F₂ on the newborn rat pulmonary arterial muscle and endothelium. *J Appl Physiol*. 95: 1979-1985 (2003).

Qiao N, Reynaud D, Demin P, Halushka PV and **Pace-Asciak CR**: The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TP α isoform in transfected COS-7 cells. *JPET*, 307: 1142-1147 (2003).

Vogan CL, Maskrey BH, Taylor GW, Henry S, **Pace-Asciak CR**, Clare AS and Rowley AF: Hepoxilins and trioxilins in barnacles: an analysis of their potential roles in egg hatching and larval settlement. *J Exp. Biol*. 206: 3219-3226 (2003).

Pang KS: Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). *Drug Metab Dispos*. 12:1507-19 (2003).

Tam D, Sun H, **Pang KS**: Influence of P-glycoprotein, transfer clearances, and drug binding on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: a theoretical analysis. *Drug Metab Dispos*. 10:1214-26 (2003).

Hata S, Wang P, Eftychiou N, Ananthanarayanan M, Batta A, Salen G, **Pang KS**, Wolkoff AW: Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake. *Am J Physiol Gastrointest Liver Physiol*. 285(5):G829-39 (2003).

Singh C, Ibrahim S, **Pang KS**, Shanti S: Implantation metastasis in a 13-year-old girl: a case report. *J Orthop Surg (Hong Kong)*. 1:94-6(2003).

Schwab AJ, Tao L, Kang M, Meng L, **Pang KS**: Moment analysis of metabolic heterogeneity: conjugation of benzoate with glycine in rat liver studied by multiple indicator dilution technique. *J Pharmacol Exp Ther*. 305(1):279-89 (2003).

Houle R, Raoul J, Levesque JF, **Pang KS**, Nicoll-Griffith DA, Silva JM: Retention of transporter activities in cryopreserved, isolated rat hepatocytes. *Drug Metab Dispos*. 4:447-51 (2003).

Tam D, Tirona RG, **Pang KS**: Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. *Drug Metab Dispos*. (4):373-83 (2003).

Verma S, Fedak PW, Ko L, Cusimano RJ, Walton NA, **Parker JD**, Yau TM. Evaluation of a novel sutureless anastomotic connector: from endothelial function to mid-term clinical and angiographic follow-up. *J Thorac Cardiovasc Surg*. 126(5):1555-60 (2003).

Liu P, Arnold JM, Belenkie I, Demers C, Dorian P, Gianetti N, Haddad H, Howlett J, Ignazewski A, Jong P, McKelvie R, Moe G, **Parker JD**, Rao V, Rouleau JL, Teo K, Tsuyuki R, White M, Huckel V, Issac D, Johnstone D, LeBlanc MH, Lee H, Newton G, Niznick J, Ross H, Roth S, Roy D, Smith S, Sussex B, Yusuf S; Canadian Cardiovascular Society. The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. *Can J Cardiol*. 19(4):347-56. (2003).

Leung RS, Bowman ME, **Parker JD**, Newton GE, Bradley TD. Avoidance of the left lateral decubitus position during sleep in patients with heart failure: relationship to cardiac size and function. *J Am Coll Cardiol*. 41(2):227-30 (2003).

Detsky ME, Azevedo ER, **Parker JD**. Left ventricular isovolumic relaxation is a predictor of left ventricular end-diastolic pressure. *Can J Cardiol*. 19(4):378-82 (2003).

Gyulkhandanyan AV, Feeney CJ, **Pennefather PS**: Modulation of mitochondrial membrane potential and reactive oxygen species production by copper in astrocytes. *J Neurochem*. 87(2):448-60 (2003)

Lee MW, Aralikatti AK, **Pennefather P**: Bilateral hypopyon following streptokinase treatment for acute myocardial infarction. *Eye*. (5):664-5 (2003).

Feeney CJ, **Pennefather PS**, Gyulkhandanyan AV: A cuvette-based fluorometric analysis of mitochondrial membrane potential measured in cultured astrocyte monolayers. *J Neurosci Methods*. 25(1-2):13-25(2003).

Yeung JY, Canning KJ, Zhu G, **Pennefather P**, MacDonald JF, Orser BA: Tonicly activated GABAA receptors in hippocampal neurons are high-affinity, low-conductance sensors for extracellular GABA. *Mol Pharmacol.* 63(1):2-8 (2003).

Petronis A. Epigenetics and bipolar disorder: new opportunities and challenges. *Am J Med Genet.* 123C(1):65-75. (2003)

Petronis A, Gottesman II, Kan P, Kennedy JL, Basile VS, Paterson AD, Pependikyte V. Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? *Schizophr Bull.* 29(1):169-78 (2003).

"R,S"

Ramji S, Lee C, Inaba T, Patterson AV, **Riddick DS**: Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines. *Cancer Res.* 63(20):6914-9 (2003).

Riddick DS, Lee C, Bhatena A, Timsit YE: The 2001 Veylien Henderson Award of the Society of Toxicology of Canada. Positive and negative transcriptional regulation of cytochromes P450 by polycyclic aromatic hydrocarbons. *Can J Physiol Pharmacol.* 81(1):59-77 (2003).

Parker KL, **Schimmer BP**: Factors in differentiation and morphogenesis of the adrenal cortex. *Topical Endocrinol* 21: 17-24 (2003).

Schimmer BP, Cordova M, Tsao J, Frigeri C. A polymorphic form of steroidogenic factor 1 associated with ACTH receptor deficiency in mouse adrenal cell mutants. In: Barsh G, Cone R, Van der Ploeg LHT (eds.), *The Melanocortin System*. vol. 994 New York, New York Academy of Sciences, 2003 pp. 147-153.

Chung C, Tallerico T, **Seeman P**: Schizophrenia hippocampus has elevated expression of chondrex glycoprotein gene. *Synapse* 50: 29-34 (2003).

Seeman P, Kapur S: Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors. *Synapse* 50: 35-40 (2003).

Seeman P, Tallerico T, Ko F: Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography. *Synapse* 49; 209-215 (2003).

Chung C, Tallerico T, **Seeman P**: Schizophrenia hippocampus has elevated expression of

chondrex glycoprotein gene. *Synapse* 50: 29-34 (2003).

Seeman P, Kapur S: Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors. *Synapse* 50: 35-40 (2003).

Seeman P, Tallerico T, Ko F: Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography. *Synapse* 49: 209-215 (2003).

Seeman P, Seeman MV.: The dopamine hypothesis of schizophrenia. In: Soares JC, Gershon S (eds) *Handbook of Medical Psychiatry*, Marcel Dekker, New York, 2003, pp. 259-266.

George SR, Ng GYK, Lee SP, Fan T, Varghese G, Wang C, Deber CM, **Seeman P**, O'Dowd BF: Blockade of G protein-coupled receptors and the dopamine transporter by a transmembrane domain peptide: Novel strategy for functional inhibition of membrane proteins in vivo. *J Pharmacol Exper Ther* 307: 481-489 (2003).

Seeman P, Seeman MV.: The dopamine hypothesis of schizophrenia. In: Soares JC, Gershon S (eds) *Handbook of Medical Psychiatry*, Marcel Dekker, New York, 2003, pp. 259-266.

George SR, Ng GYK, Lee SP, Fan T, Varghese G, Wang C, Deber CM, **Seeman P**, O'Dowd BF: Blockade of G protein-coupled receptors and the dopamine transporter by a transmembrane domain peptide: Novel strategy for functional inhibition of membrane proteins in vivo. *J Pharmacol Exper Ther* 307: 481-489 (2003).

Sellers EM, Tyndale RF, Fernandes LC: Decreasing smoking behaviour and risk through CYP2A6 inhibition. *Drug Discovery Today* 8(11): 487-493, (2003).

Schoedel KA, **Sellers EM**, Palmour R, Tyndale RF: Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. *Mol Pharmacol* 63(1): 96-104, (2003).

Gafni I, Busto UE, Tyndale RF, Kaplan HL, **Sellers EM**: The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. *J Clin Psychopharmacol* 23(2): 169-175, (2003).

Zhang W, Ramamorthy Y, Tyndale RF, **Sellers EM**: Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes P450 in vitro. *Drug Metab and Disp.* 31(6):768-772, (2003).

Howard L, Ahluwalia J, Lin S-K, **Sellers EM**, Tyndale RF: CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. *Pharmacogenetics* 13: 321-328, (2003). *Pharmacogenetics* 13: 441-442, (2003) (publishers errata).

Micu AL, Miksys S, **Sellers EM**, Koop DR, Tyndale RF: Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. *J Pharmacol and Exper Ther* 306(3):941-947, (2003).

Sellers EM, Kaplan HL, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF: The Effect of methoxsalen on nicotine and 4-(methylnitrosamino)-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. *Nicotine and Tobacco Res* 5, 1-9, (2003).

Coopamah MD, Freedman J, **Semple JW**: Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin 1 receptor antagonist. *Blood* 102(8), 2862-2867 (2003).

Coopamah M, Garvey MB, Freedman J, **Semple JW**: Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. *Transfusion Med Rev*, 17(1):69-80 (2003).

Freedman J, Lazarus AH, **Semple JW**, Garvey MB: Az intravénás immunoglobulin kezelés idoszeru kérdései. *Transzfuzóio*, 36:3-12 (2003).

Semple JW, Freedman J: Biologic modification of lymphocytes in auto- and allo-immune disorders. In: (Smit Sibinga C Th, Leij LFMH DE (eds) *Cellular Engineering and Cellular therapies*. Kluwer Academic Publishers, Dordrecht, NL. 2003 pp 55-68.

Semple JW: Pathogenic T cell responses in patients with autoimmune thrombocytopenic purpura (AITP). *J Pediat Hematol/Oncol* 25(Suppl 1),S 11-S13 (2003).

Semple JW, Lazarus AH: Anti-inflammatory effects of intravenous immunoglobulin: FcγR inhibition/blockade and non-FcγR-mediated mechanisms. In: *Intravenous immunoglobulins in the third millennium; 5th International IVIG Symposium*. Sept. 25 – 27, Interlaken, Switzerland, Parthenon Publishing, Lancaster, UK, Chapter 30, 2003.

Wong GA, **Shear NH**: Melkersson-Rosenthal syndrome associated with allergic contact dermatitis from octyl and dodecyl gallates. *Contact Dermatitis*, 49(5):266-7 (2003).

Phillips EJ, Knowles SR, **Shear NH**. Serum sickness-like reaction associated with clopidogrel. *Br J Clin Pharmacol*. 56(5):583 (2003).

Mandelcorn-Monson RL, **Shear NH**, Yau E, Sambhara S, Barber BH, Spaner D, DeBenedette MA: Related Articles, Gene, Nucleotide, Protein, Books, LinkOut Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. *J Invest Dermatol*. 121(3):550-6 (2003).

Valois M, Cooper MA, **Shear NH**: Clinical pharmacology consultations: consultation requests may be misleading -- an organized approach to drug-induced hepatitis. *Can J Clin Pharmacol*. 10(2):59-62 (2003).

Kuehl BL, Fyfe KS, **Shear NH**: Cutaneous cleansers. *Skin Therapy Lett*. (3):1-4. (2003).

Nigen S, Knowles SR, **Shear NH**: Drug eruptions: approaching the diagnosis of drug-induced skin diseases. *J Drugs Dermatol*. 2(3):278-99 (2003).

Valois M, Phillips EJ, **Shear NH**, Knowles SR: Clindamycin-associated acute generalized exanthematous pustulosis. *Contact Dermatiti*, 48(3):169 (2003).

Knowles SR, Shapiro LE, **Shear NH**: Reactive metabolites and adverse drug reactions: clinical considerations. *Clin Rev Allergy Immunol*. 24(3):229-38. (2003).

Perri D, Ito S, Rowsell V, **Shear NH**: The kidney--the body's playground for drugs: an overview of renal drug handling with selected clinical correlates. *Can J Clin Pharmacol*. 10(1):17-23. (2003).

Mandelcorn R, **Shear NH**. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? *J Am Acad Dermatol*. 48(4):525-9 (2003).

Shapiro LE, Knowles SR, Weber E, Neuman MG, **Shear NH**: Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. *Drug Safety*, 26(3):187-95 (2003)

"T"

Schoedel KA, Tyndale RF: Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. *Biochimica et Biophysica Acta* 1619(3): 283-290 (2003).

Sellers EM, **Tyndale RF**, Fernandes LC: Decreasing smoking behaviour and risk through CYP2A6 inhibition. *Drug Discovery Today* 8(11): 487-493 (2003).

Tyndale RF: Genetics of Alcoholism and Tobacco Use in Humans. *Ann of Medicine* 35: 94-121 (2003).

Schoedel KA, Sellers EM, Palmour R, **Tyndale RF**: Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. *Mol Pharmacol* 63(1): 96-104 (2003).

Gafni I, Busto UE, **Tyndale RF**, Kaplan HL, Sellers EM: The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. *J Clin Psychopharmacol* 23(2): 169-175 (2003).

Howard L A, Miksys S, Hoffmann E, Mash D, **Tyndale RF**: Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. *British J. Pharmacol.* 138: 1376-1386 (2003).

Zhang W, Ramamorthy Y, **Tyndale RF**, Sellers EM: Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes P450 in vitro. *Drug Metab and Disp.* 31(6):768-772 (2003).

Howard L, Ahluwalia J, Lin S-K, Sellers EM, **Tyndale RF**: CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. *Pharmacogenetics* 13: 321-328, (2003). *Pharmacogenetics* 13: 441-442 (2003) (publishers errata).

Miksys S, Lerman C, Shields PG, Mash DC, **Tyndale RF**: Smoking, alcoholism and genetic polymorphisms alter CYP2B6 in human brain. *Neuropharmacol* 45(1):125-135 (2003).

Micu AL, Miksys S, Sellers EM, Koop DR, **Tyndale RF**: Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. *J Pharmacol and Exper Ther* 306(3):941-947 (2003).

O'Loughlin J, DiFranza J, **Tyndale RF**, Meshefedjian G, McMillan-Davey E, Clarke P, Hanley J, Paradis G: Nicotine-dependence symptoms are associated with smoking frequency in adolescents. *Amer J Preventive Med* Oct 25(3):219-25 (2003).

Sellers EM, Kaplan HL, Ramamoorthy Y, Zeman MV, Djordjevic MV, **Tyndale RF**: The Effect of methoxsalen on nicotine and 4-(methylnitrosamino)-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. *Nicotine and Tobacco Res* 5, 1-9 (2003).

"U,V"

Seguin, B, Teranishi M, **Utrecht JP**: Modulation of D-penicillamine-induced autoimmunity in the Brown Norway rat using pharmacological agents that interfere with arachidonic acid metabolism or synthesis of inducible nitric oxide synthase. *Toxicology* 190 (3): 267-278 (2003).

Seguin, B, **Utrecht J**: The danger hypothesis applied to idiosyncratic drug reactions. *Curr Opin Allergy Clin Immunol* 3 (4): 235-242 (2003).

Shenton, JM, Teranishi M, Abu-Asab MS, Yager JA, **Utrecht JP**: Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. *Chem Res Toxicol* 16 (9): 1078-1089 (2003).

Utrecht, J: Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. *Drug Discov Today* 8 (18): 832-837 (2003).

Williams, DP, O'Donnell CJ, Maggs JL, Leeder JS, **Utrecht J**, Pirmohamed M, Park BK: Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro. *Chem Res Toxicol* 16 (10): 1359-1364 (2003).

Sanyal S, Wintle RF, Nuttley WM, Summers SH, Arvan R, Bigras E, Merz D, Hebert T, van der Kooy D, Schafer WR, Culotti GJ, **Van Tol HHM**: Dopamine modulates plasticity of distinct sensory responses in *C. elegans*. *EMBO J*, 23(2):473-82 (2003).

Schoots O, **Van Tol HHM**: The human dopamine D4 receptor repeat sequences modulate expression. *Pharmacogenomics J*. 3(6):343-8 (2003).

Wong AHC, **Van Tol HHM**: The dopamine D4 receptor and mechanisms of antipsychotic atypicality. *Prog Neuropsychopharmacol Biol Psychiat*. 27(7):1091-9 (2003).

Wong AHC, **Van Tol HHM**: Schizophrenia: From phenomenology to neurobiology. *Neurosci Biobehav Rev*. 27(3):269-306 (2003).

Wong AHC, Klempan T, Kawczynski W, Barr CL, Lakatoo S, Wong M, Buckle C, Trakalo J, Boffa E, Oak J, Azevedo M-H, Dourado A, Coelho I, Macedo A, Vicente A, Valente J, Ferreira CP, Pato CN, Kennedy JL, **Van Tol HHM**: The identification of candidate genes for psychosis in rat models, and possible association between schizophrenia and 14-3-? gene. *Mol. Psychiat* 8(2), 156-166 (2003).

Oak James N, **Van Tol Hubert HM**. The dopamine system. In: Offermanns S & Rosenthal W (eds.) *Molecular Pharmacology: An encyclopedic reference*. Springer-Verlag, Berlin, 2003, pp310-315.

"W"

Chang A, Li PP, **Warsh JJ**: Altered cAMP-dependent protein kinase subunit immuno-labeling in postmortem brain from patients with bipolar affective disorder. *J Neurochem* 84: 781-791(2003).

Andreopoulos S, Li PP, Siu KP, Kish SJ, **Warsh JJ**: Altered CTX-catalyzed and endogenous [32P]ADP-ribosylation of stimulatory G protein as Isoforms in postmortem bipolar affective disorder temporal cortex. *J Neurosci Res* 72: 638-645 (2003)

Chang A, Li PP, **Warsh JJ**: cAMP-dependent protein kinase (PKA) subunit mRNA levels in postmortem brain from patients with bipolar affective disorder. *Mol Brain Res* 116: 27-37 (2003)

Park PS, Wells JW. Monomers and oligomers of the M2 muscarinic cholinergic receptor purified from Sf9 cells. *Biochemistry*. 42(44):12960-71 (2003).

Laposa RR, Henderson JT and Wells PG. Tetracycline-dependent regulation of formamidopyrimidine DNA glycosylase (fpg) in transgenic mice conditionally reduces oxidative DNA damage in vivo. *FASEB Journal*:

* Online full paper: *FASEB Journal* express article 10.1096/fj.02-0689fje, 20 May 2003:

[http://www.fasebj.org/cgi/reprint/02-](http://www.fasebj.org/cgi/reprint/02-0689fjev1?ijkey=M6Jojmxt2CRLw&keytype=ref&siteid=fasebj)

[0689fjev1?ijkey=M6Jojmxt2CRLw&keytype=ref&siteid=fasebj](http://www.fasebj.org/cgi/reprint/02-0689fjev1?ijkey=M6Jojmxt2CRLw&keytype=ref&siteid=fasebj)

* Print journal summary article: *FASEB J* 17: 1343-1345, 2003.

Wong, AHC and Van Tol HHM: The dopamine D4 receptor and mechanisms of antipsychotic atypicality. *Prog Neuropsychopharmacol Biol Psychiat*. 27(7):1091-9 (2003).

Wong AHC, Van Tol HHM: Schizophrenia: From phenomenology to neurobiology. *Neurosci Biobehav Rev*. 27(3):269-306 (2003).

Wong AHC, Klempan T, Kawczynski W, Barr CL, Lakatoo S, Wong M, Buckle C, Trakalo J, Boffa E, Oak J, Azevedo M-H, Dourado A, Coelho I, Macedo A, Vicente A, Valente J, Ferreira CP, Pato CN, Kennedy JL, Van Tol HHM: The identification of candidate genes for psychosis in rat models, and possible association between schizophrenia and 14-3-? gene. *Mol. Psychiat* 8(2), 156-166 (2003).

Woodland C, Koren G, Wainer IW, Batist G, Ito S: Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. *Can J Physiol Pharmacol*. 81(8):800-5 (2003).

Woodland C, Koren G, Ito S: From bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example. *J Clin Pharmacol*. 43(7):743-50 (2003).

"X,Y,Z"

Zack M, Poulos CX, Fragopoulos F, MacLeod CM. Effects of negative and positive mood primes on priming of alcohol words in young drinkers with high and low anxiety sensitivity. *Exp Clin Psychopharmacol*. 11(2):176-85 (2003).
